Superselective Intra-arterial Chemotherapy of Advanced Paranasal Sinus Tumors

Lee, Ya-Yen; Dimery, Isaiah W.; Tassel, Pamela Van; Pena, Charles De; Blacklock, Jerry Bob; Goepfert, Helmuth

doi:10.1001/archotol.1989.01860280101026

Cited by 90 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 This approach, using superselective, indwelling catheters, combined with systemic chemotherapy and followed by surgery and/or RT, has produced a 30% CR rate and an 80% major response rate, as reported by Lee at al. 33 Orbital exenteration was required in 21% of patients treated in that manner, and the overall projected 5-year survival rate was 50%. Others have used the IA route of delivery for chemotherapy extensively in the setting of head and neck squamous cell carcinomas with other localization.…”

Section: Discussionmentioning

confidence: 99%

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

Papadimitrakopoulou

Ginsberg

Garden

et al. 2003

Cancer

View full text Add to dashboard Cite

A cobalt‐catalyzed reductive coupling of terminal alkynes, RCCH, with activated alkenes, R′CHCH2, in the presence of zinc and water to give functionalized trans‐disubstituted alkenes, RCHCHCH2CH2R′, is described. A variety of aromatic terminal alkynes underwent reductive coupling with activated alkenes including enones, acrylates, acrylonitrile, and vinyl sulfones in the presence of a CoCl2/P(OMe)3/Zn catalyst system to afford 1,2‐trans‐disubstituted alkenes with high regio‐ and stereoselectivity. Similarly, aliphatic terminal alkynes also efficiently participated in the coupling reaction with acrylates, enones, and vinyl sulfone, in the presence of the CoCl2/P(OPh)3/Zn system providing a mixture of 1,2‐trans‐ and 1,1‐disubstituted functionalized terminal alkene products in high yields. The scope of the reaction was also extended by the coupling of 1,3‐enynes and acetylene gas with alkenes. Furthermore, a phosphine‐free cobalt‐catalyzed reductive coupling of terminal alkynes with enones, affording 1,2‐trans‐disubstituted alkenes as the major products in a high regioisomeric ratio, is demonstrated. In the reactions, less expensive and air‐stable cobalt complexes, a mild reducing agent (Zn) and a simple hydrogen source (water) were used. A possible reaction mechanism involving a cobaltacyclopentene as the key intermediate is proposed.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

Papadimitrakopoulou

Ginsberg

Garden

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

“…Using more careful superselective catheterization, they then treated 24 patients with advanced paranasal sinus tumours by combined superselective IA and systemic chemotherapy, yielding an immediate satisfactory tumour response rate of 91%. Significantly, eight patients avoided craniofacial surgery as a result of their response to treatment (29).…”

Section: Superselective Ia Infusionmentioning

confidence: 99%

“…Significant advances in vascular radiology techniques and new devices, such as fluoroscopy units and angiographic catheters, make possible safe, accurate and repeated superselective IA chemotherapy (29,40,41). These techniques and tools continue to be improved, making it possible to perform safer and more accurate superselective IA chemotherapy than ever before.…”

Section: Superselective Ia Infusionmentioning

confidence: 99%

Intra-arterial chemoradiotherapy for head and neck cancer

Homma¹,

Onimaru²,

Matsuura³

et al. 2015

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Intra-arterial chemotherapy has been used to treat localized malignant neoplasms in patients with head and neck cancer for over 50 years as the head and neck region is particularly well suited to regional chemotherapy. Early intra-arterial chemotherapy did not prove its efficacy. In addition, the additional complications associated with establishing and maintaining arterial access have further dampened enthusiasm for this approach. Subsequent significant advances in vascular radiology techniques and the development of new devices, such as fluoroscopy units and angiographic catheters, have made possible safe, accurate and repeated superselective intra-arterial chemotherapy. Intra-arterial infusion of high-dose cisplatin with systemic neutralization by intravenous sodium thiosulfate (RADPLAT) is a theoretically attractive approach to the treatment of advanced head and neck cancer. However, a Dutch trial comparing intra-arterial and intravenous chemoradiotherapy for advanced head and neck cancer showed that RADPLAT was not superior to intravenous chemoradiotherapy. Therefore, further investigation of RADPLAT, including the refinement of the indications for its application, is needed.

show abstract

“…Intra-arterial infusion of chemotherapeutic agents was first carried out in the 1960s [25,26]; however, technical difficulties and poor initial results prevented the technique from gaining popularity until the 1980s, when Lee et al [27] reported a 91% tumor response rate in 24 patients treated with combined intra-arterial cisplatin and i.v. chemotherapy for advanced paranasal sinus carcinoma.…”

mentioning

confidence: 99%

“…Several authors subsequently reported on the use of intra-arterial chemotherapy alone, but CR rates remained disappointingly low, in the range of 7.7%-33% [27][28][29][30][31]. The main criticism leveled at regional chemotherapy techniques was that there was no clear survival benefit over conventional systemic chemotherapy but a considerably greater risk of local toxicity.…”

mentioning

confidence: 99%

RADPLAT: An Alternative to Surgery?

2006

View full text Add to dashboard Cite

Head and neck cancer frequently presents at a late stage, leading to a poor prognosis despite optimal treatment with surgery and/or radiotherapy. Chemotherapy for advanced disease has shown little benefit as a single-modality treatment, and the use of concurrent chemoradiation is limited by problems with severe toxicity at higher doses. RADPLAT is the acronym used to describe a new technique, combining intra-arterial delivery of cisplatin with systemic neutralization by i.v. sodium thiosulphate, and concurrent radiotherapy. This allows very high cisplatin dose intensities to be used while potentially minimizing adverse systemic effects. Initial results suggest that excellent locoregional control rates are achievable in patients with unresectable disease, with a favorable side-effect profile when compared with conventional chemoradiation protocols. In addition, RADPLAT may potentially be of benefit in selected patients with resectable disease, allowing for preservation of organ function and quality of life without compromising locoregional control or survival. While current phase II data are encouraging, phase III randomized controlled trials are required in order to directly compare RADPLAT with i.v. chemoradiation therapy, the current standard of care. This article reviews the evolution of the RADPLAT concept, from initial clinical trials to its current application in the treatment of patients with advanced head and neck cancer.

show abstract

Superselective Intra-arterial Chemotherapy of Advanced Paranasal Sinus Tumors

Cited by 90 publications

References 8 publications

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma

Intra-arterial chemoradiotherapy for head and neck cancer

RADPLAT: An Alternative to Surgery?

Contact Info

Product

Resources

About